Reevaluation of some double-blind, randomized studies of dexibuprofen (Seractil): a state-of-the-art overview. Studies in patients with lumbar vertebral column syndrome, rheumatoid arthritis, distortion of the ankle joint, gonarthrosis, ankylosing spondylitis, and activated coxarthrosis.
This article presents a reevaluation of studies previously performed regarding the efficacy and safety of dexibuprofen (Seractil; S(+)-ibuprofen) for use in patients with inflammatory or degenerative diseases. Using appropriate standardized measures (univariate and multivariate analysis with the Mann-Whitney statistic with confidence intervals), the authors were able to compare the effects of treatment in different diseases. For the primary criterion and for the combined analysis of all efficacy criteria, one-sided equivalence was proved in all six studies reviewed.
Rahlfs
V W
VW
idv-Data Analysis and Study Planning, Gauting/Munich, Germany.
Stat
C
C
D000843:Ankle Joint; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004311:Double-Blind Method; D006801:Humans; D007052:Ibuprofen / Q000627:therapeutic use*; D007719:Knee Joint; D008159:Lumbar Vertebrae; D015207:Osteoarthritis, Hip / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D013237:Stereoisomerism
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007052:Ibuprofen